The things They Told You Around SB431542 Is definitely Extremely Wrong

There was no history to suggest a recent viral illness in any of the cases and routine surveillance for cytomegalovirus was negative. Our program did recommend flu vaccinations against both H1N1 and seasonal flu around this period. Another potential contributory factor is exposure to anti-TNF alpha agents and lymphocyte depleting antibodies for induction, although this was a factor in only two of the three cases. Both anti-TNF and lymphodepleting antibodies were used prior to supplemental islet infusions in 23 other subjects who http://www.selleck.cn/products/ipi-145-ink1197.html have not developed alopecia, and are routinely used in first islet transplants. Recurrent alopecia has been reported in association with the use of etanercept in rheumatoid arthritis (21). Theoretically, http://www.selleckchem.com/products/SB-431542.html lymphodepletion could lead to homeostatic proliferation, precipitating autoimmune disease. In mouse models, newly generated T cells (recent thymic emigrants) have a strong potential to become homeostatically activated and cause autoimmune disease in the setting of lymphopenia. This involves certain key receptors (PD-1 and BTLA) and requires adequate lymphoid stroma (since knockout mice with no lymph nodes are protected) to cause this homeostatic activation and autoimmunity (22,23). The two cases who received rabbit antithymocyte globulin induction had prolonged lymphopenia (with lymphocyte counts http://www.selleckchem.com/products/byl719.html with most presenting within 21 months of exposure. We have observed two cases of Graves disease in islet transplant recipients who have been treated with alemtuzumab (unpublished observation). Given the small number of cases and the multiple potential contributors to the development of alopecia following islet transplantation in type 1 diabetic subjects, it is difficult to discern the exact cause of alopecia in each of these cases. One common factor appears to be the use of a tacrolimus-based immunosuppressant regimen and type 1 diabetes. The need to control both allo- and autoimmunity in islet transplantation is clear and has been the rationale for the use of potent lymphodepleting induction agents; yet emerging evidence suggests that lymphodepletion could precipitate autoimmunity. Although this is a novel risk for patients undergoing islet transplantation which should be discussed with candidates, it is encouraging that all patients exhibited improvements over time, regardless of whether immunosuppression was changed.